Global Active Pharmaceutical Ingredient Market (2021 to 2030) - by Type of Manufacturer, Type, Type of Synthesis, Type of Drug, Therapeutic Application, Distribution Channel and Region - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Nov 11, 2021--
The “Active Pharmaceutical Ingredient Market Research Report: By Type of Manufacturer, Type, Type of Synthesis, Type of Drug, Therapeutic Application, Distribution Channel - Global Industry Revenue Estimation to 2030” report has been added to ResearchAndMarkets.com’s offering.
The global active pharmaceutical ingredient market value stood at $184,311.2 million in 2020, and it is expected to surge to $357,005.7 million by 2030, demonstrating a CAGR of 6.9% from 2021 to 2030.
Mushrooming Geriatric Population: According to the World Health Organization (WHO), the surge in the average life expectancy in recent years has caused a sharp rise in the population of older people. As per the World Population Ageing 2020 report published by the United Nations Department of Economic and Social Affairs (UNDESA), the population of people aged 65 years and above will rise from 727 million in 2020 to more than 1.5 billion by 2050. As geriatric people are vulnerable to chronic and acute illnesses due to their weak immune systems, their soaring population is driving the requirement for effective drugs, which is consequently fueling the expansion of the API market.
Increasing Occurrence of Chronic Diseases: With people following sedentary lifestyles and the prevalence of obesity increasing, the incidence of various chronic diseases, such as diabetes, is soaring across the globe. According to the WHO, 422 million people are currently living with it and the disease claims 1.6 million lives every year. Being a long-term disease, patients require constant medication, particularly insulin.
The COVID-19 pandemic has amplified the worldwide demand for pharmaceutical products. Due to the increasing number of patients, drug research and development activities, especially those aimed at finding an effective vaccine, have surged. Additionally, the API market has been positively impacted by the rising demand for such products during the pandemic. For instance, the Pharmaceutical Export Promotion Council (PHARMEXCIL) of India recorded a significant increase in the cost of penicillin, one of the most-well-known antibiotic APIs, from $6.16 per unit in January 2020 to $8.69 per unit in just one month.
The oncology category dominated the API market during the last few years, within the therapeutic application segment. The high incidence of cancer is resulting in the rising requirement for highly potent APIs (HPAPIs). As per the American Cancer Society, by 2021-end, nearly 1.9 million new cases of cancer and 608,570 related deaths will be reported in the U.S. Similarly, as per the WHO, there were 2,003,789 cases of various types of cancers in Southeast Asia in 2018. Moreover, the disease claimed the lives of 1,336,026 people in the same year.
Geographically, North America is predicted to dominate the API market in the forthcoming years due to the rising prevalence of and awareness on chronic and lifestyle-associated illnesses, surging focus of governments on generic drugs, soaring requirement for specialty drugs and biologics, rapid technological advancements, and increasing number of pharmaceutical R&D activities in the region. For instance, as per the Centers for Disease Control and Prevention (CDC), in 2018, chronic illnesses cost $3.5 trillion to the U.S. healthcare system.
- Partnerships and mergers & acquisitions
- Technological advancement in API manufacturing
- Rising geriatric population
- Increasing incidence of chronic diseases
- Growing importance of generics
- Impact analysis of drivers on market forecast
- High manufacturing costs
- Unfavorable drug price control policies
- Stringent regulations
- Impact analysis of restraints on market forecast
- Cipla Ltd.
- Dr. Reddy’s Laboratories Ltd.
- Teva Pharmaceutical Industries Limited
- Aurobindo Pharma Limited
- Novartis AG
- Pfizer Inc.
- Bristol-Myers Squibb Company
- Glenmark Life Sciences Limited
- Johnson & Johnson
- Merck & Co. Inc.
- AbbVie Inc.
- Eli Lilly and Company
- GlaxoSmithKline plc
- Takeda Pharmaceutical Company Limited
- Amneal Pharmaceuticals Inc.
- AstraZeneca plc
- Sun Pharmaceutical Industries Ltd.
- Alkem Laboratories Limited
- Mylan N.V.
- Lupin Limited
- STADA Arzneimittel AG
- Mallinckrodt plc
- Glenmark Life Sciences Limited
- MSN Laboratories Pvt. Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/jcejhf
View source version on businesswire.com:https://www.businesswire.com/news/home/20211111005863/en/
Laura Wood, Senior Press Manager
email@example.comFor E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2021.
PUB: 11/11/2021 11:11 AM/DISC: 11/11/2021 11:11 AM